EUVIMEDEUVIMED entdecken
Crossref

Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites

Ping Li, Qingyuan Wu, Yuanhao Zhou, Xiaojuan Hu, Yan Tang, Yuanyuan Wang, Weijiao Fan, Yiyi Shan, Kexin Yu, Jie Wang, Shibing Wang, Xiao Ye und 2 weitere

Nano Research · 2025-12 · 18 (12) · 94907986

DOI: 10.26599/nr.2025.94907986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Research, 2025-12. Verfasst von Ping Li und 13 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-associated fatty liver disease (MAFLD), a global health burden with limited therapeutic options beyond lifestyle changes, urgently needs novel strategies. We engineered exosome-like nanovesicles (HNVs) from dried honeysuckle (Lonicera japonica), exhibiting significantly more uniform size distribution than conventional herbal extracts and characteristic nanovesicle morphology. Orally delivered HNVs, enriched with bioactive metabolites, dramatically inhibited increased fat vacuoles, lipid droplet deposition, and collagen fibrosis in the livers of mice with MAFLD induced by high-fat diet (HFD). Mechanistically, HNVs orchestrate a dual gut-liver intervention: (1) Restoring gut barrier integrity, slashing serum LPS by 1.58-fold and quelling hepatic inflammation; (2) Remodeling gut microbiota to suppress bile salt hydrolase (BSH), elevating taurochenodeoxycholic acid (TCDCA) 2.07-fold. This microbial shift reprograms enterohepatic signaling by inhibiting the FXR-FGF15-FGFR4 axis, thereby boosting hepatic cholesterol catabolism via bile acid synthases. Critically, efficacy is strictly microbiota-dependent: abolished by antibiotics and fully transferable via fecal microbiota transplantation (FMT) from HNV-treated donors. Presenting the first natural nanovesicle platform that concurrently targets gut barrier repair and metabolic reprogramming, HNVs establish a pioneering, multi-targeted therapeutic paradigm for MAFLD, directly linking gut microbial ecology to hepatic pathophysiology with high translational potential.

Zitieren

APA

Li, P., Wu, Q., Zhou, Y., Hu, X., Tang, Y., Wang, Y., Fan, W., Shan, Y., Yu, K., Wang, J., Wang, S., Ye, X., Liu, H., & Mou, X. (2025). Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites. Nano Research, 18(12), 94907986. https://doi.org/10.26599/nr.2025.94907986

Vancouver

Li P, Wu Q, Zhou Y, Hu X, Tang Y, Wang Y, et al. Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites. Nano Research. 2025;18(12):94907986. doi:10.26599/nr.2025.94907986

BibTeX
@article{Li2025,
  author = {Li, Ping and Wu, Qingyuan and Zhou, Yuanhao and Hu, Xiaojuan and Tang, Yan and Wang, Yuanyuan and Fan, Weijiao and Shan, Yiyi and Yu, Kexin and Wang, Jie and Wang, Shibing and Ye, Xiao and Liu, Huiyu and Mou, Xiaozhou},
  title = {Honeysuckle-derived exosome-like nanovesicles ameliorate metabolic-associated fatty liver disease by modulating gut microbiota and its metabolites},
  journal = {Nano Research},
  year = {2025},
  volume = {18},
  number = {12},
  pages = {94907986},
  doi = {10.26599/nr.2025.94907986}
}
Kostenlos starten →